Rhythm Pharmaceuticals Q3 EPS $(0.61) Beats $(0.72) Estimate, Sales $92.128M Beat $84.349M Estimate
Benzinga Newsdesk 1 day ago
NewsEarningsEarnings Beats
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.72) by 15.28 percent. This is a 25.61 percent increase over losses of $(0.82) per
Rhythm Pharmaceuticals (NASDAQ:RYTM) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.72) by 15.28 percent. This is a 25.61 percent increase over losses of $(0.82) per share from the same period last year. The company reported quarterly sales of $92.128 million which beat the analyst consensus estimate of $84.349 million by 9.22 percent. This is a 79.59 percent increase over sales of $51.298 million the same period last year.